Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (September 2025)
26 slides from Vivani Medical's investor presentation, Sep 9, 2025
Slide 1: Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.
Viva Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.
Slide 2: Disclaimers
Disclaimers ‘The following sides and any accompanying oral presentation contain frwaré-looking statements within the meaning of Section 27A ofthe Secures Act of 1933, as amended, and Section 21€ ofthe Secures Exchange Act of 1934, a5 amended, which ate intended tobe covered bythe “safe harbor create
Slide 3: The obesity market is evolving
The obesity market is evolving What wil take to be successful in the future? In addition to the two approved products on the market, there are over 50 in clinical development. All of these are injectables or orals. A differentiated route of administration presents opportunities to access untapped se
Slide 4: Vivani's differentiated product candidates are designed to address unmet needs and expand the market
Vivani's differentiated product candidates are designed to address unmet needs and expand the market Vivani Market Challenges @ Suboptimal outcomes Poor medication adherence (<50%) leads to loss of efficacy and rapid weight rebound & Tolerability issues Dose fluctuations and pharmacokinetic (PK) var
Slide 5: Vivani Medical, Inc.
Vivani Medical, Inc. Acclinical stage innovator uniquely positioned to address the future challenges and opportunities of an evolving obesity market diseases via unique route of administration, improved patient adherence, Nasdaq: VANI © Our focus: Enhance patient outcomes and GLP-1 market uptake in
Slide 6: Company pipeline utilizing NanoPortal platform
Company pipeline utilizing NanoPortal platform If approved, Vivani products may compete in markets with large commercial potential et ET =) Canine & Feline Obesity lod “Partnered > <—————Vivand. > sippy reary enamine emanece perig rot Sener ‘ert oat ase or pea orc foe Da notre esr wre fr pone rou PR
Slide 7: Good things come in small packages
Good things come in small packages GLP-1 implant & applicator Simple administration, in-office procedure to insert the implant Comfortably under the skin for twice yearly dosing designed to produce Wegowt-level efficacy NanoPortal device elements Designed to assure adherence ¥ Long.term delivery Sta
Slide 8: NanoPortal delivers smooth, near-constant drug release
NanoPortal delivers smooth, near-constant drug release In Vitro Release-Rate (ygiday) Invitro release-rate of exenatide implant (n=6). ° Day 1 timepoint includes cumulative release over the g i: aia a first day ineiuging a separately measured 1st hour of Time (Days) felease, which was ~7 pg forthe h
Slide 9: Release Rate (µg/day)
Release Rate (xglday) In vitro and in vivo performance of 12-week GLP-1 implant configuration Upper Lower 8% laf Mean Ey cy wo 7 Time (Day) In tr rlease-rate of exenatide implant (n=1) nica vous ace Incided for each timepann Each Week canst of two 22hour tera anda ‘Seay inten Values are mean = 1 SD
Slide 10: GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study
GLP-1 NanoPortal implant reduced liver fat by 82% in preclinical study Liver fat reduction in high fat diet-induced obese ‘mice. Liver fat 9 area for exenatide implant vs sham implant 12 weeks after a single administration. Values ‘are mean # SE Vivani Liver fat (% Area) 35.0 30.0 25.0 200 15.0 10.0
Slide 11: Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects
Preclinical GLP-1 NanoPortal implant is associated with durable body weight effects 2 2% hs Tas g e200) °F Vehicle Implant (Control) 9=18 TT 40.9 | + Vehicle Implant (Control), =5 Seeeremeeey ; ees & b Time (Oays) Time (Days) ‘Weight difference from control in healthy Sprague-Daviley Rats. % weight
Slide 12: First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1
First-in-human GLP-1 NanoPortal clinical trial: LIBERATE-1 Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerabilty assessment and full pharmacokinetic 18.55 years old; overweight or obese (BMI 27-40) characterization, Changes in weight also assessed, Otherwise healthy (no 72D, normal
Slide 13: LIBERATE-1 topline results summary
LIBERATE-1 topline results summary Implant well-tolerated No serious adverse events in the study No clinically meaningful initial burst ¢ Encouraging release profile No evidence of dose dumping Potential for durable long-term delivery confirmed Primary study objectives were met: } eurther NanoPortal
Slide 14: Vivani Lead Program: NPM-139
Vivani Lead Program: NPM-139 Semaglutide Implant for Chronic Weight Management Targeting the Rapidly Growing GLP-1 Market Vivani
Slide 15: Priority clinical development program: NPM-139
Priority clinical development program: NPM-139 Development of once- or twice-yearly semaglutide implant for chronic weight management in obese or overweight patients 12) GLP-1 products ‘generated >$14B in sales in 2024 for chronic weight management. The obesity market is expected to grow at 32% CAGR
Slide 16: Persistence and adherence are critical to securing desired long-term health outcomes
Persistence and adherence are cri to securing desired long-term health outcomes Persistence data comparing obesity therapies suggest room for improvement across the board, including for semagiutide. @ The opportunity for an additional 60% improvement in persistence for semaglutide is significant and
Slide 17: Semaglutide discontinuation leads to rapid hunger-induced weight rebound
Semaglutide discontinuation leads to rapid hunger- induced weight rebound Vivant z 3 i S2eokoftratment ss weak restment phate vam Time sine randomisation) STEP 1 Extension: Semaglutide Withdrawal ‘wlding etal, 2022 Diabetes, Obesity, and Metabolism sapenquetn shee: th lice,
Slide 18: Semaglutide implant successfully delivers durable weight loss in preclinical model for >7 months
Semaglutide implant successfully delivers durable weight loss in preclinical model for >7 months ‘Weight difference versus control group in healthy Sprague-Dawley rats. weight change from baseline for NPM-139 (semaglutide implant) corrected to control (sham implant). Implants from 4 animals were rem
Slide 19: Patient and prescriber research indicates strong adoption potential for a long-acting GLP-1 implant
Pa’ adoption potential for am implant nt and prescriber research indicates strong ature, 6-month GLP-1 56% of GLP-1 patients responded “likely” Currently on a GLP-1 therapy (12324) or “definitely” to get a GLP-1 implant if FDA 33% approved, prescriber recommended, and covered by insurance GLP. thera
Slide 20: NPM-139 clinical and regulatory development: Near-term plan builds on recent wins
NPM-139 clinical and regulatory development: Near-term plan builds on recent wins Milestone Status ‘Announced LIBERATE-1 completed and met the primary study objectives August 2025 Reported positive weight loss in preclinical study with semaglutide pert ‘August 2025 Disclosed proposed clinical progra
Slide 21: Proposed NPM-139 Phase 1 study design
Proposed NPM-139 Phase 1 study design Primary Objectives Key Inclusion/Exclusion Criteria Safety/tolerability assessment and pharmacokinetic 18-55 years old; overweight or obese (BMI 27-40) characterization Otherwise healthy (no T2D) seroan and ‘Treatment 4 Weeks) Randomize (-14 days) ror v [NPM-139
Slide 22: Proposed NPM-139 Phase 2 study design
Proposed NPM-139 Phase 2 study design Randomize Run-In (20 weeks) {y _ Randomized Treatment Period (16 or 24 weeks) -unblinded Dose escalation at week intervals — 2
Slide 23: The Vivani executive leadership team
The Vivani executive leadership team Donald Dwyer, MBA. Lisa Porter, MD Chief Business Officer Chief Medical Office Adam Mendelsohn PhD CEO/Director Truc Le, MBA “Anthony Baldor, MS, MBA CChief Operations Officer Chief Financial Officer Vivani
Slide 24: Vivani headquarters and GMP manufacturing facility
Vivani headquarters and GMP manufacturing facility
Slide 25: Guaranteed adherence. Improved outcomes.
Guaranteed adherence. — Improved outcomes. @ Only GLP-1 implant in development © Convenient once- or twice-yearly dosing expected to address GLP-1 adherence and tolerability challenges @ Unique modality designed to expand the market by — underserved & unaddressed populations Vivani
Slide 26: Thank You
Thank You Company Contact: Donald Dwyer, Chief Business Officer info@vivani.com Investor Relations Contact: Jami Taylor, investor Relations Advisor investors@vivani.com
Vivani Medical — Investor Presentation (September 2025) on 6ix